Y-Lan Truong

Ms. Y-Lan Truong

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
BGBahgat Z Gerges
Bahgat Z Gerges
JRJoel Rosenblatt
Joel Rosenblatt
YTY-Lan Truong
Y-Lan Truong
RRRuth A. Reitzel
Ruth A. Reitzel
RHRay. Y. Hachem
Ray. Y. Hachem
Issam I RaadIssam I Raad
Issam I Raad
Antiseptic wound ointments are widely used to treat dermal wounds that are microbially contaminated. Polygalacturonic acid (PG)+caprylic acid (CAP) is a novel combination that has been shown to eradicate biofilms. We developed a novel PG+CAP ointment and compared the biofilm eradication capability and cytotoxicity of PG+CAP with that of commercially available antiseptic wound ointments. We used a well‐established biofilm model to quantitatively assess the eradication of organisms following exposure to the wound ointments for 2 hours. PG+CAP ointment completely eradicated Candida albicans, multidrug‐resistant Pseudomonas aeruginosa, and methicillin‐resistant Staphylococcus aureus biofilms, whereas MediHoney, polyhexamethylene biguanide (PHMB), and benzalkonium chloride (BZK) ointments failed to eradicate all biofilms within 2 hours. We assessed cytotoxicity by exposing L‐929 fibroblasts to extracts of each ointment; Trypan blue exclusion was used to assess cell viability, and Alamar blue conversion was used to assess metabolic function. After exposure to PG+CAP and MediHoney, fibroblast viability was 96.23% and 95.23%, respectively (Trypan blue), and was comparable to untreated cells (98.77%). PHMB and BZK showed reduced viability (83.25% and 77.83%, respectively, p < 0.05). Metabolic activity results followed a similar pattern. Cytotoxicity of PG+CAP ointment towards erythrocytes was comparable to saline. PG+CAP ointment seems to be safe and can rapidly eradicate microbial biofilm; thus, PG+CAP ointment merits further in vivo testing as a potential antimicrobial wound ointment.

24 February 2025 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
BGBahgat Z Gerges
Bahgat Z Gerges
JRJoel Rosenblatt
Joel Rosenblatt
YTY-Lan Truong
Y-Lan Truong
Ying JiangYing Jiang
Ying Jiang
Issam I RaadIssam I Raad
Issam I Raad
Candida colonization and biofilms are significant contributors to impaired wound healing. Consequently, improved treatments are needed to eradicate Candida biofilms in wounds. Wounds present complex biofilm extracellular matrix environments, with microbial cells frequently enmeshed in matrices comprising wound exudate macromolecular gels. We evaluated the ability of a polygalacturonic and caprylic acid (PG + CAP) ointment to eradicate Candida albicans, C. parapsilosis, C. glabrata, C. tropicalis, and C. auris biofilms in a fibrin gel wound biofilm model of the complex wound biofilm environment. Hypochlorous acid (HOCl) is a disinfecting antimicrobial agent that is widely used as wound irrigant, and this was used as a comparator. A single treatment with PG + CAP reduced the number of viable organisms in the C. albicans and C. glabrata biofilms by over 5 log10, in the C. parapsilosis and C. auris biofilms by over 4 log10, and in the C. tropicalis biofilm by 3.85 log10. PG + CAP was superior (p < 0.01) to HOCl in eradicating all Candida species biofilms, except for C. auris, for which both treatments fully eradicated all viable organisms. The use of HOCl in Candida-colonized wounds should include consideration of the extracellular matrix load in the wound bed. PG + CAP warrants further study in wounds compromised by Candida biofilms.

5 November 2024 in Journal of Medical Mycology
Verified
Journal Article
Closed access
YTY-Lan Truong
Y-Lan Truong
JRJoel Rosenblatt
Joel Rosenblatt
BGBahgat Gerges
Bahgat Gerges
YJYing Jiang
Ying Jiang
IRIssam Raad
Issam Raad

3 June 2026 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
Issam I RaadIssam I Raad
Issam I Raad
YTY-Lan Truong
Y-Lan Truong
BGBahgat Z Gerges
Bahgat Z Gerges
YJYing Jiang
Ying Jiang
RHRay. Y. Hachem
Ray. Y. Hachem
JRJoel Rosenblatt
Joel Rosenblatt
Antimicrobial central venous catheters (CVCs) help prevent CVC-related bloodstream infection (CRBSI), and their effectiveness depends on sustaining broad antimicrobial activity in serum. A new CVC containing minocycline, rifampin, and chlorhexidine (MRC) was recently approved, complementing existing minocycline-rifampin (MR) and chlorhexidine-silver-sulfadiazine (CSiSz) CVCs. This study compared the elution profiles of minocycline, rifampin, and chlorhexidine from these three CVC types in serum and assessed resulting antimicrobial durability against CRBSI pathogens. MRCs were prepared by impregnation with minocycline and rifampin, followed by sequential chlorhexidine coating; commercial MR and CSiSz CVCs served as comparators. CVCs were immersed in plasma for 24 h, and then in serum for 3 weeks. At baseline and weekly intervals, CVC segments were analyzed for antimicrobial content and challenged with clinical CRBSI isolates. MRC retained higher minocycline and rifampin levels than MR and higher chlorhexidine levels than CSiSz after 3 weeks in serum. Correspondingly, MRC demonstrated superior inhibition of gram-negative colonization ( Klebsiella pneumoniae , Escherichia coli , Acinetobacter baumannii ) and Enterococcus faecalis at week 3 ( P ≤ 0.028). They also showed greater activity against Candida species (spp.) ( C. albicans , C. glabrata ) at weeks 2 and 3 ( P ≤ 0.005). MR and MRC CVCs completely prevented methicillin-resistant Staphylococcus aureus and S. epidermidis colonization for 3 weeks, outperforming CSiSz ( P = 0.003). In conclusion, slow elution from MRC CVCs resulted in significantly enhanced antimicrobial durability against gram-negative bacteria, E. faecalis , and Candida spp. MR and MRC CVCs provided equivalent, sustained protection against Staphylococcal colonization, both surpassing CSiSz CVCs.

27 November 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
YTY-Lan Truong
Y-Lan Truong
BGBahgat Z Gerges
Bahgat Z Gerges
JRJoel Rosenblatt
Joel Rosenblatt
Issam I RaadIssam I Raad
Issam I Raad
IV connectors are ubiquitous access junctions in vascular access circuits. Unlike vascular catheters and IV lines made from soft polymers, connectors are made from rigid polycarbonate (PC) to prevent deformation during manipulation. In accessing PC connectors (PCCs) for infusion, PCCs are vulnerable to becoming microbially contaminated. Here we report development of a novel antimicrobial polycarbonate coating for preventing microbial colonization of IV connectors. The FDA recently approved a new antimicrobial polyurethane catheter coating that comprised Minocycline (M), Rifampin (R), and Chlorhexidine (C). We spray-coated MRC onto PCCs as sequential laminate layers of M, R and C in PC or blend PC and polycarbonate-urethane copolymers. MRC coated PCCs were immersed in tubes filled with 50% serum + 50% saline to simulate elution of the coatings. After 7 days (typical interval of use prior to replacement of IV connectors), eluted connectors were exposed to challenge inocula of key CLABSI pathogen clinical isolates for 24 hours and the number of colonizing microbes were enumerated by sonication, serial dilution, plating and colony counting. Non-coated PCCs were positive controls. The absence of microbial colonization of the MRC IV connectors demonstrates the efficacy and durability of the novel MRC polycarbonate laminate coating. MRC coated connectors merit further testing in vitro and in vivo for their potential to prevent CLABSI. Joel Rosenblatt, PhD, Novel Anti-Infective Technologies, LLC: Licensed Technology Issam I. Raad, Distinguished Professor, Novel Anti-Infective Technologies, LLC: Technology License

27 November 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
BGBahgat Z Gerges
Bahgat Z Gerges
YTY-Lan Truong
Y-Lan Truong
JRJoel Rosenblatt
Joel Rosenblatt
RHRay. Y. Hachem
Ray. Y. Hachem
ACAnne-Marie P. Chaftari
Anne-Marie P. Chaftari
Issam I RaadIssam I Raad
Issam I Raad
Gram negative (GN) bacterial infections are on the rise in patients with cancer (PWC). There is an urgent need for new therapies to address the rise of infections caused by multidrug resistant (MDR) GN pathogens. Taniborbactam is a β-lactamase inhibitor in combination with cefepime may offer a potential treatment option for patients with serious GN bacterial infections. This study aimed to evaluate the in vitro activity of a novel combination of cefepime-taniborbactam and comparators against recent Gram-negative clinical isolates from PWC. Recent GN clinical isolates from PWC were tested against cefepime-taniborbactam and comparators. Clinical and laboratory Standards Institute (CLSI) approved broth microdilution method was used. Appropriate ATCC controls were included. MIC90, and percent of susceptibility calculations were made using FDA breakpoints when available. We tested 100 GN isolates and further testing is ongoing. Cefepime-taniborbactam and comparators antibiotics susceptibility percentage (S: %), and MIC90 are shown in the table below. Cefepime-taniborbactam demonstrated highly potent activity against all of tested Enterobacterales including extended spectrum Beta-lactamase (ESBL), and carbapenem-resistant Enterobacterales (CRE) as well as against P. aeruginosa and Stenotrophomonas maltophilia. At a provisional breakpoint of 16/4 mg/L, cefepime-taniborbactam showed highest activity against all tested isolates when compared to cefepime and other comparators, including activity against ESBL, CRE, MDR P. aeruginosa and S. maltophilia. Our data demonstrate that cefepime-taniborbactam has promising activity against clinically significant multidrug-resistant (MDR) GN bacterial pathogens isolated from PWC and it showed high activity compared to other commonly used broad spectrum antimicrobial agents. Joel Rosenblatt, PhD, Novel Anti-Infective Technologies, LLC: Licensed Technology Issam I. Raad, Distinguished Professor, Novel Anti-Infective Technologies, LLC: Technology License